Royalty Pharma plc (NASDAQ:RPRX) saw an upside of 1.80% to close Monday at $36.13 after adding $0.64 on the day. The 5-day average trading volume is 1,038,180 shares of the company’s common stock. It has gained $36.37 in the past week. An average of 2,966,595 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,466,480.
RPRX’s 1-month performance is -6.11% or -$2.35 on its low of $34.86 reached on 10/06/21. The company’s shares have touched a 52-week low of $34.80 and high of $53.23, with the stock’s rally to the 52-week high happening on 01/19/21. YTD, RPRX has lost -27.81% or -$13.92. However, the current price is down -32.12%% from the 52-week high price.
A Backdoor Way To Profit From Today’s Crypto Bull Market
In any crypto bull market, there's a lot of money to be made.
But what if we told you the best opportunities are not cryptocurrencies themselves… but instead, simply crypto stocks?
This strategy is simply and ridiculously easy.
Here are 6 ways to gain exposure to crypto outside the norm. This is arguably the safest bet you can make.
On Sep 29, 13 days have gone by since the last insider trading activity for Royalty Pharma plc (RPRX). RIGGS RORY B (Director) most recently sold 63,777 shares at $36.35 per share on Sep 29. This transaction cost the insider $2,318,494. Director, RIGGS RORY B, sold 24,648 shares at a price of $36.50 on Sep 29. Then, on Sep 28, Director RIGGS RORY B sold 40,000 shares at a price of $36.75 per share. This transaction amounted to $1,470,088.
The company’s PE ratio for the last five years has touched a high of 41.22 and a low of 7.174. RPRX stock has a beta of 0.00. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 9.81 while the price-to-book (PB) in the most recent quarter is 2.57.
Royalty Pharma plc pays an annual dividend of $0.68 per share. Its dividend yield is 1.88% and the payout ratio is 25.90%. RPRX’s most recent quarterly dividend payment was made on Sep. 15, when it paid $0.17 a share compared with prior rate of $0.17, down 0.0% from last year’s. The company has boosted its dividend for the last 2 consecutive years with the latest dividend increase of $0.02 reported on Monday January 11 2021.
It is projected that Royalty Pharma plc’s next ex-dividend date will be on 23-Nov. RPRX is expected to distribute $0.17 as its next dividend.
Royalty Pharma plc’s quick ratio for the period ended June 29 was 9.50, with the current ratio over the same period at 9.50 meaning that RPRX stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 1.02, while the total debt to equity was 0.00 while for the period ending June 29; Royalty Pharma plc’s operating margin was 79.00%. The firm’s gross profit as reported stood at $526.95 million against revenue of $2.12 billion.
For the quarterly period ending June 29 this year, Royalty Pharma plc’s cash and short-term investments amounted to $911.39 million against total debt of $5.83 billion. Net income and sales went down compared to those figures reported in the previous quarter. Analysts expected RPRX to announce $0.69 per share in earnings in its latest quarter, but it posted $0.71, representing a 2.90% surprise. EBITDA for the quarter stood at more than $755.48 million. RPRX stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 6.11 billion, with total debt at $5.83 billion. Shareholders hold equity totaling $607.17 million
Let’s look briefly at Royalty Pharma plc (RPRX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 11 October was 45.34% to suggest the stock is trending Neutral, with historical volatility in this time period at 20.61%.
The stock’s 5-day moving average is $35.62, reflecting a +2.73% or $0.96 change from its current price. RPRX is currently trading -6.18% above its 20-day SMA, -9.70% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -5.42% and -25.67% respectively.
Stochastic %K and %D was 27.13% and 21.27% and the average true range (ATR) pointed at 0.92. The RSI (14) points at 42.50%, while the 14-day stochastic is at 40.58% with the period’s ATR at 0.95. The stock’s 9-day MACD Oscillator is pointing at -0.10 and -0.48 on the 14-day charts.
In the most recent analyst report for Royalty Pharma plc (NASDAQ: RPRX), Tigress Financial launched coverage with a Buy rating. Analysts offering their rating for RPRX stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate RPRX as a “sell,”, while 3 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 4 have offered a “buy” rating.
What is RPRX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $46.00 and a high of $56.00, with their median price target at $52.50. Looking at these predictions, the average price target given by analysts is for Royalty Pharma plc (RPRX) stock is $51.67.